anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The PROTECT Pregnancy Study was designed to pilot direct-to-patient data collection methods for use in postmarketing surveillance into the foetal effects of maternal medication use in pregnancy. This study which recruited women between October 2012 and January 2014 explored whether women in participating EU countries were willing to provide information via the internet to enable prospective collection of medication exposure data and information about other life style factors during pregnancy. The study's main objective was to assess the extent to which data collected directly from pregnant women via the Internet and an interactive voice response system (IVRS) would provide information on medication use and other potential risk factors throughout pregnancy that is suitable for research purposes.

Pregnant women were recruited for the study using a variety of methods and were asked about use of medications, alcohol and tobacco, recreational drugs, herbals and other factors that could negatively affect birth outcome. The pilot study revealed that women would indeed volunteer to provide information on medication and lifestyle factors during pregnancy, with 2521 women enrolling from four countries over 8-18 months. The four countries include the United Kingdom (UK), The Netherlands (NL), Denmark (DK) and Poland (PL). Of those who enrolled in the PROTECT pregnancy study, only 2066 provided any data, with all but one providing data via internet.
Antigenic fraction is prepd. from a portion of a culture of pathogens e.g. Vibro cholerae, Salmonella typhimurium, Malleomyces mallei or Pseudomonas mallei, the portion corresponding to the peak of 280 nm on the u.v. absorption spectrum, and which, opposed to an immune serum produced in an animal from the same culture, give the band or pair of bands of precipitation nearest the antigen source in the diffusion test in a gel medium and the immuno-electrophoretic analysis test, in which one cultivates the organism; lyses the culture obtained and centrifuges the liberated products after purification. Product is used as a vaccine against cholera. The organisms are pref. lysed using Gallut's method or by ultrasonics. Precipitation by CCl3. CO2H purifies the product. After centrifugation, the supernatant is neutralized then dialysed against distilled water.
Patients receive cabozantinib s-malate PO QD on days 1-28 and nivolumab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 21 cycles, patients receive nivolumab IV over 30 minutes every 4 weeks in the absence of disease progression or unacceptable toxicity. After progression, patients may receive cabozantinib s-malate PO, nivolumab IV, and ipilimumab IV at the part II RP2D for 4 cycles followed by cabozantinib s-malate PO QD and nivolumab IV every 2 weeks or 4 weeks if post-cycle 21 in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography or magnetic resonance imaging and collection of blood samples throughout the trial. Patients may also undergo echocardiography at baseline and biopsies throughout the trial.
Ustekinumab, Tacrolimus and Sirolimus. Ustekinumab: 45 mg for adults who weight 100 kg or less; 90 mg for adults who weight greater than 100 kg. Tacrolimus: Level determined according to Blood and Marrow Transplant (BMT) Program standard operating procedures. Sirolimus: The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program.
A cariprazine oral soluble film composition, a preparation method and a use thereof are provided. The oral soluble film composition includes an active ingredient, a film-forming material, and a plasticizer, wherein the active ingredient is a mixture of one or more selected from the group consisting of cariprazine, pharmaceutically acceptable salt thereof, and inclusion compound thereof. The oral soluble film composition of the instant disclosure has advantages of thin thickness, good texture, stable properties, instant solubility in oral cavity without drinking water, and fast oral administration absorption. Moreover, the preparation process is simple, the load efficiency is high, and the content uniformity of the ingredient is good. The oral soluble film composition of the instant disclosure is beneficial to improve behaviors such as bad compliance, medicine hiding, and medicine spitting/vomiting of schizophrenia patients, and it is especially suitable for patients having difficulty with swallowing. The prospect of marketization is good.
A cosmetic skin treatment method includes providing a patch configured to be used in both a cleansing mode and a treatment mode. The patch includes a polymeric matrix and a reinforcing member. The polymeric matrix includes at least one cosmetically active compound and at least one water-absorbent compound. The patch is configured to adhere to dry skin and also to adhere to skin when at least one of the patch and skin are moistened. The method also includes selecting at least one of the cleansing mode and the treatment mode. When the cleansing mode is selected, the method further includes applying the patch to an areas of dry skin so that the polymeric matrix adheres to the skin for a time sufficient to allow at least one impurity in the area of skin to become attached to the polymeric matrix. Thereafter, the patch is removed from the area of the skin while said at least one impurity is attached to the polymeric matrix. When the treatment mode is selected, the method further includes moistening at least one of the patch and an area of the skin. Then, the patch is applied to the area of skin so that the patch adheres to the area of skin. After applying the patch, the cosmetically active compound is allowed to contact the area of skin. A cleansing and treatment patch is also disclosed.
Hyaluronic acid administered as an intra-articular injection under ultrasound guidance as a series of three weekly injections to the affected knee. 3 weekly injections are of ultra high molecular weight hyaluronan (16mg) in a 2mL injection.
The invention relates to a gefitinib nanosuspension, a preparation method and application thereof, belonging to the field of pharmaceutical formulation. The invention adopts a precipitation method combined with high-speed shearing and high-pressure homogenization to prepare the nano-suspension. The prescription is optimized by adopting a single-factor investigation method, the indexes of the preparation, such as particle size, PDI, Zeta potential, form and the like, are investigated, and the dissolution rate of the medicament is investigated by an in-vitro release experiment. The gefitinib nanosuspension is characterized in that: comprising gefitinib, lecithin and Sodium Dodecyl Sulfate (SDS). The particle size of the medicine in the suspension is 100-500 nm. The concentration of gefitinib in the suspension is 0.25-1 mg/ml. The nano suspension has the advantages of simple prescription, excellent effect and simple and controllable preparation method, improves the solubility of the medicine in water, is beneficial to improving the administration form of the medicine, and is beneficial to oral administration and absorption of the medicine.
BACKGROUND AND PURPOSE: Fibromyalgia is a chronic syndrome marked by intense musculoskeletal pain often refractory to pharmacological treatment. Although studies have shown that hypnosis improves fibromyalgia pain, gaps in experimental design limit their reliability. This work aimed to evaluate the effects of hypnosis on pain, mental health, sleep, and quality of life in participants with fibromyalgia chronic pain.
METHODS: In this prospective, parallel, randomized, controlled, blindly-evaluated trial, participants of both sexes (n = 49) diagnosed with fibromyalgia and with moderate to severe chronic pain attended 8 weekly 1-h sessions with a hypnotherapist. For the hypnosis group (n = 24), sessions consisted in induction of hypnotic trance followed by suggestions to promote analgesia. For the control group (n = 25), sessions consisted in casual unscripted conversation. Participants were assessed at baseline (7 days before), post-intervention (7 days after), and follow-up (3 months after). The primary outcome was pain intensity. The secondary outcomes were the sensory and affective dimensions of pain; pain unpleasantness; pain catastrophizing; anxiety and depression; sleep quality; fibromyalgia impact; and quality of life.
RESULTS: Hypnosis significantly reduced pain scores both at post-intervention and follow-up in comparison with baseline. The analgesic effect of hypnosis combined with pharmacological treatment lasted for at least 3 months and was superior to analgesia promoted by first- and second-line pharmacological treatment alone. Hypnosis significantly improved all parameters evaluated as secondary outcomes both at post-intervention and follow-up without inducing adverse events.
CONCLUSION: Our results corroborate that clinical hypnosis is an effective and feasible tool for managing chronic pain and other symptoms of fibromyalgia.
Daily 2x 5g Hybrid Product, produced by Carbiotix AB. Hybrid Product is available as powder, which can be easily dissolved in water.
Disclosed is household paper. The household paper comprises a paper base layer, and an independent first functional medication layer and an independent second functional medication layer, both of which are formed on the paper base layer. The first functional medication layer is located at the outermost surface of the household paper and contains a heat sensitizer. The second functional medication layer contains functional medications having the efficacy of nourishing, maintaining and caring skin. According to the invention, the independent first functional medication layer and the independent second functional medication layer are employed in the household paper, which allows the heat sensitizer to be distributed concentratedly to reach good temperature sensing effect. Compared to conventional household paper, the application amount of the household paper in the invention is smaller for achieving the same temperature sensing effect. In addition, the heat sensitizer is transferred onto skin while the household paper is applied on the skin; skin surface is quickly warmed to make the pores on the skin surface open; and the stratum corneum of the skin surface is softened, which is advantageous for absorption of the functional medication through the pores and the skin surface, so that the functional medications can be further absorbed and effective availability of the functional medications is improved.
Structures that bind to a selected target are prepared having two or more different effector molecules joined to each other by a joining component. At least one of the effector molecules such as an antibody binds to the target and at least one of the other effector molecules such as an enzyme is therapeutic. The joining component may be a liposome, protein, dendrimer polymer or complementary nucleic acid chains. The joining component may be of sufficient length and/or flexibility to permit the therapeutic molecule to physically interact with the target at the same time as the binding molecule binds with the target. The structures may be used in disease treatment, immunoassays and sensors. For in vivo genetic manipulation of cells, the liposome joining component is filled with a plurality of genetic manipulation complexes that contain a polynucleotide having a sequence for recombination and a binding site, a DNA binding protein bound to the binding site and a motor protein conjugated to the polynucleotide. Prophospholipase may be on the surface of the liposome, and when activated cleaves the liposome to release the complex.
A continuous process for manufacturing a continuous floss brush comprises steps of first applying a polymer solution at a repeated preselected distance interval to a continuous length of floss yarn under tension and solidifying the polymer while the floss yarn is under tension to produce a continuous floss product of yarn sections which stretch under slight tension separated by thread sections which do not significantly stretch under tension. The floss yarn is treated to expand the yarn sections to form brush sections. The passage of a predetermined number of segments comprising thread and brush portions is determined while the continuous floss brush is under substantially zero tension using a optical detector. Finally, a length of the continuous floss segments containing the predetermined number of segments comprising thread and brush portions is cut for packaging. Preferably, a dye marker is applied to at least a portion of the thread portion, whereby the accuracy of the optical detection of the thread portions of the continuous floss brush is increased. The yarn is a nylon yarn, and the yarn sections are expanded by treatment with heat and water vapor when under zero tension to yield a product with a highly expanded brush portion which is stretched under slight tension. The floss brush product comprises a continuous length of floss having segments comprising alternating portions of yarn sections which stretch under slight tension separated by thread sections which do not significantly stretch under tension, at least a portion of each thread section being preferably marked with a dye.
<P>PROBLEM TO BE SOLVED: To provide an aroma or the like emitting body burning in a stable state, facilitating an ignition without dispersing a kindling coal, and completely burning out to the last.  <P>SOLUTION: A burning material 1 is integrally attached to the surface of a base sheet 2. The burning material 1 contains necessary active gradients gradually spreading the burning without forming a flame and volatilizing the contents by the heat in burning. Among the active ingredients of the burning material 1 are components of an incense, an aroma effective for aroma therapy, insecticide or insect repellent components, and the like and, when being attached to the base sheet 2, the burning material is made into an appropriately flat shape. It is preferable to use an incombustible material for the base sheet 2.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Administration of LOP Placebo (0 h, 12 h, 24 h, 36 h, 48 h), Colon Transit (0 h, 12 h, 24 h, 36 h, 48 h), Placebo (0 h, 12 h, 24 h, 36 h, 48 h) and SSP (48 h). To assess WGT, OCT and CTT under placebo condition.
Microscopic hematuria (MH) is a frequent biological finding. In most cases, the etiology is benign, symptomatic and reversible. The diagnostic approach allows classifying hematuria as glomerular or non-glomerular. For non-glomerular hematuria, the risk of urinary tract neoplasia is 5% and should always be evaluated1. To use resources efficiently, patients requiring additional and invasive exam must be identified and distinguished from those who will only require a follow up. This article reviews the diagnostics approach of MH by integrating the new recommendations of the American urology association published in 2020.
Exercise intervention. The experimental group increased their energy expenditure according to American College of Sports Medicine and WHO-based physical activity recommendations for all adults to promote clinically significant weight loss and for additional health benefits: 300 min of moderate-intensity aerobic training throughout the week (WHO, 2010; Swift et al. 2014). Participants underwent five 60 min moderate-intensity cycling sessions per week for a period of 8 weeks, 40 sessions in total. Each session involved 5 min of warm up at 40 Watts, cycling for 50 min at a speed that increased their HR to a target HR obtained at 50-60% of peak VO2, and a 5 min of cool down at 40 Watts.
An essential requirement for sustaining male fertility is maintaining an adequate number of stem spermatogonia, the foundation of spermatogenesis. To achieve this, when the stem cells divide, some progeny must remain stem spermatogonia while other progeny differentiate. It is obvious that the correct balance between self-renewing replication and differentiation of stem spermatogonia is crucial to male fertility, and there is a indirect evidence that GDNF plays an important role in maintaining this balance in the normal mature testis. However, almost nothing is known about the in vivo regulation of this balance in the mature organ, of the specific function of GDNF in the adult testis, or if physiological changes in GDNF expression significantly affect the replication or differentiation of the stem cells. To address these critical issues, a unique mouse model that allows GDNF signaling to the stem spermatogonia to be specifically and reversibly inhibited in vivo by an ATP antagonist. With this model, the first direct evidence that GDNF is required for maintaining the stem spermatogonial pool in a normal mature testis. Additionally, the investigators have shown that when inhibition of GDNF signaling is reversed, the stem cells begin to rebuild the stem cell pool. Importantly, our data demonstrate that some stem spermatogonia are lost when GDNF signaling is inhibited for as little as 2 days, while other stem cells survive for up to 11 days. This suggests that factors intrinsic or extrinsic to the stem cells modulate the response to GDNF. Using this new mouse model the mechanisms responsible for the loss of stem spermatogonia proliferation and regeneration will be investigated along with GDNF signaling and inhibition. At the end of all of this these studies will be done on waste tissue obtained from normal men and men with infertility who otherwise have testicular surgery for therapeutic purposes.
Chronic plaque psoriasis is the most common form of psoriatic skin disease; however, there is growing evidence that other variants including scalp, nail, inverse, and palmoplantar psoriasis are prevalent, undertreated, and are correlated with an increased risk of psoriatic arthritis that may result in significant morbidity with functional impairment and greater impairment in quality of life. Therefore, the main aim of the study is to provide robust efficacy and safety data on guselkumab treatment for palmoplantar non-pustular psoriasis. The study comprises of a Screening Phase (4 Weeks \[Week -4 to 0\]), a Treatment Phase (up to Week 48) and a post-treatment follow-up phase (up to Week 56). Key efficacy assessments include physician assessments and patient-reported outcomes questionnaires. Safety evaluations will include 12-lead electrocardiogram at baseline, pregnancy testing and monitoring of vital signs at all visits and recording of adverse events throughout the study. Also, participants will be evaluated for signs and symptoms of active tuberculosis at all visits including follow-up visit. Biomarker assessments will include the evaluation of relevant markers in serum for all participants. The study will have an overall duration of 56 weeks.
Severe acute pancreatitis (AP) is a life-threatening pancreatic inflammatory disease with a high mortality rate (∼40%). Existing pharmaceutical therapies in development or in clinical trials showed insufficient treatment efficacy due to their single molecular therapeutic target, poor water solubility, short half-life, limited pancreas-targeting specificity, etc. Herein, acid-responsive hollow mesoporous Prussian blue nanoparticles wrapped with neutrophil membranes and surface modified with the N,N-dimethyl-1,3-propanediamine moiety were developed for codelivering membrane-permeable calcium chelator BAPTA-AM (BA) and trypsin activity inhibitor gabexate mesylate (Ga). In the AP mouse model, the formulation exhibited efficient recruitment at the inflammatory endothelium, trans-endothelial migration, and precise acinar cell targeting, resulting in rapid pancreatic localization and higher accumulation. A single low dose of the formulation (BA: 200 μg kg-1, Ga: 0.75 mg kg-1) significantly reduced pancreas function indicators to close to normal levels at 24 h, effectively restored the cell redox status, reduced apoptotic cell proportion, and blocked the systemic inflammatory amplified cascade, resulting in a dramatic increase in the survival rate from 58.3 to even 100%. Mechanistically, the formulation inhibited endoplasmic reticulum stress (IRE1/XBP1 and ATF4/CHOP axis) and restored impaired autophagy (Beclin-1/p62/LC3 axis), thereby preserving dying acinar cells and restoring the cellular "health status". This formulation provides an upstream therapeutic strategy with clinical translation prospects for AP management through synergistic ion homeostasis regulation and pancreatic autodigestion inhibition.
Neutrophils are increasingly implicated in chronic inflammation and metabolic disorders. Here, we show that visceral adipose tissue (VAT) from individuals with obesity contains more neutrophils than in those without obesity and is associated with a distinct bacterial community. Exploring the mechanism, we gavaged microbiome-depleted mice with stool from patients with and without obesity during high-fat or normal diet administration. Only mice receiving high-fat diet and stool from subjects with obesity show enrichment of VAT neutrophils, suggesting donor microbiome and recipient diet determine VAT neutrophilia. A rise in pro-inflammatory CD4+ Th1 cells and a drop in immunoregulatory T cells in VAT only follows if there is a transient spike in neutrophils. Human VAT neutrophils exhibit a distinct gene expression pattern that is found in different human tissues, including tumors. VAT neutrophils and bacteria may be a novel therapeutic target for treating inflammatory-driven complications of obesity, including insulin resistance and colon cancer.
Following cast application, little is known regarding the need to split the cast, either in a univalve (a split along a single side of the cast) or bivalve (a split along both sides of the cast) fashion. Theoretically, the splitting of the cast allows for expansion and soft tissue swelling. However, review of the literature yields a paucity of evidence demonstrating the efficacy of splitting a cast. In a study by Nietosvaara et. al, a retrospective examination of 109 pediatric patients initially treated with closed cylindrical casting for closed forearm fractures were evaluated. Of these 109 patients, one-sixth required the initial cast to be split, trimmed, or removed secondary to post-traumatic swelling.

However, the splitting of a cast is not without risks in itself. Once the initial swelling dissipates, a univalved or bivalved cast can become excessively loose. This loosening has been associated with a loss of reduction. If the loss or reduction is substantial, it may require a re-reduction or operation to correct. In addition, with every use of the cast saw a patient is placed at risk for iatrogenic cast saw injury. Thermal burns and abrasions from cast saws can cause lifelong emotional and physical scars for a patient. They can also be an inciting event for litigation against the hospital and or provider, with settlements averaging greater than $12,000 per centimeter of cast saw injury.